You have heard the rumors about the CRISPR cure. In 2026, we are still waiting for the "London Patient" miracle to become a pharmacy product. Gene editing is expensive ($2 million per patient). It works. But it isn't scalable.
Furthermore, we are seeing a resurgence of "AIDS exceptionalism" fatigue. Donors are tired. The public is distracted by climate migration and AI wars. The result? A 15% funding cut to PEPFAR (the U.S. President's Emergency Plan for AIDS Relief) that quietly went through last fall. aids 2026
The problem isn't dying of AIDS in 2026. It's living with HIV and facing a frail body at 60. Geriatric HIV care is the specialty no one trained for, and we are scrambling to catch up. You have heard the rumors about the CRISPR cure
In 2026, the largest cohort of people living with HIV in North America and Western Europe are over 55 years old. It works
We are discovering something cruel. Even with an undetectable viral load, the chronic inflammation caused by three decades of infection (or long-term ART use) is causing heart attacks, bone fractures, and cancers to appear 10 to 15 years earlier than in their HIV-negative peers.
We have split the world into two populations: those who can access a pharmacy or a clinic, and those who cannot.
If you had told someone in the 1980s that we would still be writing about AIDS in 2026, they would have been exhausted. If you told them that we would be close to ending it, they wouldn’t have believed you.
